10Feb 2023
More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics

More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics

The advent of a new generation of targeted cancer drugs requires a radically different design of early clinical trials. Here, the authors discuss why new clinical trial designs are needed and what is being done. Such innovative trials can lead to similar outcomes for cancer patients with fewer side effects, while at the same time reducing the cost of cancer care.

  • #oncology

Like

Save

Share